Iovance Biotherapeutics Names Noah Berkowitz Chief Medical Officer

Iovance Biotherapeutics has appointed Noah Berkowitz as its new Chief Medical Officer, effective September 30, 2026. The company also granted inducement equity awards for up to 450,000 shares with options priced at $14.82.